Bronchoalveolar lavage fluid reveals factors contributing to the efficacy of PD-1 blockade in lung cancer
暂无分享,去创建一个
S. Imoto | T. Aoshi | T. Irie | D. Okuzaki | S. Uematsu | K. Fujimoto | T. Nii | A. Kumanogoh | S. Koyama | T. Hirashima | M. Tamiya | T. Kumagai | Y. Takeda | Yumi Kinugasa-Katayama | T. Shiroyama | K. Masuhiro | N. Okamoto | K. Nishino | Y. Adachi | A. Osa | Yujiro Naito | Hidekazu Suzuki | T. Morita | T. Hirai | Akiko Kajihara
[1] A. Flügel,et al. The lung microbiome regulates brain autoimmunity , 2022, Nature.
[2] Bowen Diao,et al. Comprehensive Analysis of the Expression and Prognosis for Laminin Genes in Ovarian Cancer , 2021, Pathology & Oncology Research.
[3] T. Aoshi,et al. Microfluidics sorting enables the isolation of an intact cellular pair complex of CD8+ T cells and antigen-presenting cells in a cognate antigen recognition-dependent manner , 2021, PloS one.
[4] John G Doench,et al. CARM1 Inhibition Enables Immunotherapy of Resistant Tumors by Dual Action on Tumor cells and T cells. , 2021, Cancer discovery.
[5] P. Van Loo,et al. Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition , 2021, Cell.
[6] Richard Bonneau,et al. Lower airway dysbiosis affects lung cancer progression. , 2020, Cancer discovery.
[7] T. Greiling,et al. Host–microbiota interactions in immune-mediated diseases , 2020, Nature Reviews Microbiology.
[8] M. Vasson,et al. Characterisation of microbiota in saliva, bronchoalveolar lavage fluid, non-malignant, peritumoural and tumour tissue in non-small cell lung cancer patients: a cross-sectional clinical trial , 2020, Respiratory Research.
[9] D. Isla,et al. The Influence of Lung Microbiota on Lung Carcinogenesis, Immunity, and Immunotherapy. , 2020, Trends in cancer.
[10] Rongchang Chen,et al. A Refined View of Airway Microbiome in Chronic Obstructive Pulmonary Disease at Species and Strain-Levels , 2020, bioRxiv.
[11] K. Ishii,et al. Antigen-specific Mucosal Immunity Regulates Development of Intestinal Bacteria-mediated Diseases. , 2019, Gastroenterology.
[12] S. Loi,et al. Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade , 2019, Clinical Cancer Research.
[13] A. Drilon,et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[14] J. Emile,et al. Role of antibiotic use, plasma citrulline and blood microbiome in advanced non-small cell lung cancer patients treated with nivolumab , 2019, Journal of Immunotherapy for Cancer.
[15] D. Ito,et al. Semaphorin 7A promotes EGFR-TKI resistance in EGFR mutant lung adenocarcinoma cells. , 2018, JCI insight.
[16] Fan Zhang,et al. Fast, sensitive, and accurate integration of single cell data with Harmony , 2018, bioRxiv.
[17] Richard Bonneau,et al. Airway Microbiota Is Associated with Upregulation of the PI3K Pathway in Lung Cancer , 2018, American journal of respiratory and critical care medicine.
[18] Eric C. Polley,et al. Interaction between the microbiome and TP53 in human lung cancer , 2018, Genome Biology.
[19] Kaushal Parikh,et al. Use of broad-spectrum antibiotics impacts outcome in patients treated with immune checkpoint inhibitors , 2018, Oncoimmunology.
[20] J. Erb-Downward,et al. The Lung Microbiota of Healthy Mice Are Highly Variable, Cluster by Environment, and Reflect Variation in Baseline Lung Innate Immunity , 2018, American journal of respiratory and critical care medicine.
[21] L. Zitvogel,et al. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[22] Mark D. Robinson,et al. Compensation of Signal Spillover in Suspension and Imaging Mass Cytometry , 2018, Cell systems.
[23] J. Wargo,et al. The gut microbiota influences anticancer immunosurveillance and general health , 2018, Nature Reviews Clinical Oncology.
[24] R. Greil,et al. Impact of antibiotic treatment on immune-checkpoint blockade efficacy in advanced non-squamous non-small cell lung cancer , 2018, Oncotarget.
[25] J. Tosello,et al. Tumor Necrosis Factor α and Regulatory T Cells in Oncoimmunology , 2018, Front. Immunol..
[26] Jing Zhang,et al. Difference of lower airway microbiome in bilateral protected specimen brush between lung cancer patients with unilateral lobar masses and control subjects , 2018, International journal of cancer.
[27] Laurence Zitvogel,et al. Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors , 2018, Science.
[28] E. Le Chatelier,et al. Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients , 2018, Science.
[29] Riyue Bao,et al. The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients , 2018, Science.
[30] J. Horton,et al. A Phase II Study of Pembrolizumab in EGFR‐Mutant, PD‐L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[31] C. Niu,et al. Prognostic value of MICA/B in cancers: a systematic review and meta-analysis , 2017, Oncotarget.
[32] G. Freeman,et al. Interleukin‐17A Promotes Lung Tumor Progression through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD‐1 Blockade , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[33] S. Uematsu,et al. Intestinal microbiota link lymphopenia to murine autoimmunity via PD-1+CXCR5−/dim B-helper T cell induction , 2017, Scientific Reports.
[34] Jeffrey L. Curtis,et al. Bacterial Topography of the Healthy Human Lower Respiratory Tract , 2017, mBio.
[35] M. Atkins,et al. Predictive biomarkers for checkpoint inhibitor-based immunotherapy. , 2016, The Lancet. Oncology.
[36] J. Chun,et al. Characterization of microbiome in bronchoalveolar lavage fluid of patients with lung cancer comparing with benign mass like lesions. , 2016, Lung cancer.
[37] Hao Chen,et al. Cytofkit: A Bioconductor Package for an Integrated Mass Cytometry Data Analysis Pipeline , 2016, PLoS Comput. Biol..
[38] John C Marioni,et al. A step-by-step workflow for low-level analysis of single-cell RNA-seq data with Bioconductor , 2016, F1000Research.
[39] Paul J. McMurdie,et al. DADA2: High resolution sample inference from Illumina amplicon data , 2016, Nature Methods.
[40] I. Melero,et al. Tumor-Produced Interleukin-8 Attracts Human Myeloid-Derived Suppressor Cells and Elicits Extrusion of Neutrophil Extracellular Traps (NETs) , 2016, Clinical Cancer Research.
[41] H. Maecker,et al. Platinum‐conjugated antibodies for application in mass cytometry , 2016, Cytometry. Part A : the journal of the International Society for Analytical Cytology.
[42] F. Martinez,et al. The Microbiome and the Respiratory Tract. , 2016, Annual review of physiology.
[43] Jason B. Williams,et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy , 2015, Science.
[44] F. Ginhoux,et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota , 2015, Science.
[45] C. Rudin,et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.
[46] Xinmin Yan,et al. Discovery and validation of potential bacterial biomarkers for lung cancer. , 2015, American journal of cancer research.
[47] J. Yewdell,et al. CXCR3 chemokine receptor enables local CD8(+) T cell migration for the destruction of virus-infected cells. , 2015, Immunity.
[48] B. Marsland,et al. Host–microorganism interactions in lung diseases , 2014, Nature Reviews Immunology.
[49] T. Yen,et al. IL-6-stimulated CD11b+CD14+HLA-DR− myeloid-derived suppressor cells, are associated with progression and poor prognosis in squamous cell carcinoma of the esophagus , 2014, Oncotarget.
[50] M. Cheng,et al. Microbiota modulate tumoral immune surveillance in lung through a γδT17 immune cell-dependent mechanism. , 2014, Cancer research.
[51] Jae-Hun Kim,et al. Improvement of orthotopic lung cancer mouse model via thoracotomy and orotracheal intubation enabling in vivo imaging studies , 2014, Laboratory animals.
[52] A. Fields,et al. Utility and Applications of Orthotopic Models of Human Non‐Small Cell Lung Cancer (NSCLC) for the Evaluation of Novel and Emerging Cancer Therapeutics , 2013, Current protocols in pharmacology.
[53] J. Egen,et al. Peripheral prepositioning and local CXCL9 chemokine-mediated guidance orchestrate rapid memory CD8+ T cell responses in the lymph node. , 2013, Immunity.
[54] U. V. von Andrian,et al. CXCR3 chemokine receptor-ligand interactions in the lymph node optimize CD4+ T helper 1 cell differentiation. , 2012, Immunity.
[55] Kyle Bittinger,et al. Topographical continuity of bacterial populations in the healthy human respiratory tract. , 2011, American journal of respiratory and critical care medicine.
[56] G. Stathopoulos,et al. Granulocyte colony-stimulating factor expression as a prognostic biomarker in non-small cell lung cancer. , 2011, Oncology reports.
[57] T. Aoshi,et al. Expression mapping using a retroviral vector for CD8+ T cell epitopes: definition of a Mycobacterium tuberculosis peptide presented by H2-Dd. , 2005, Journal of immunological methods.
[58] C. Galanos,et al. Cutting Edge: A Murine, IL-12-Independent Pathway of IFN-γ Induction by Gram-Negative Bacteria Based on STAT4 Activation by Type I IFN and IL-18 Signaling1 , 2002, The Journal of Immunology.
[59] J. Finke,et al. The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumor. , 1998, Journal of immunology.
[60] J. Farber. Mig and IP‐10: CXC chemokines that target lymphocytes , 1997, Journal of leukocyte biology.
[61] Y. Ohmori,et al. Tumor necrosis factor-alpha induces cell type and tissue-specific expression of chemoattractant cytokines in vivo. , 1993, The American journal of pathology.
[62] J. Lunceford,et al. IFN- γ –related mRNA profile predicts clinical response to PD-1 blockade , 2017 .
[63] A. Didier,et al. [Incidence and characteristics of bronchial colonisation in patient with lung cancer: a retrospective study of 388 cases]. , 2011, Revue des maladies respiratoires.